Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases

Modern Pathology

Volumn 23, Issue 7, 2010, Pages 961-971

  Harbaum, Lars ^a   Pollheimer, Marion J ^a   Bauernhofer, Thomas ^a   Kornprat, Peter ^a   Lindtner, Richard A ^a   Schlemmer, Andrea ^a   Rehak, Peter ^a   Langner, Cord ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

cell line; clinical significance; colorectal cancer; immunohistochemistry; prolactin receptor; survival; targeted therapy

Indexed keywords

PROLACTIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; WESTERN BLOTTING; ADENOCARCINOMA; BIOSYNTHESIS; CANCER STAGING; COLORECTAL TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, PROLACTIN; TISSUE ARRAY ANALYSIS; KAPLAN-MEIER ESTIMATE;

EID: 77954244966     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.83     Document Type: Article

References (37)

1. Boyle P, Levin B. World Health Organization. World Cancer Report 2008. IARC Press: Lyon, 2008, pp 374-378.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Hampton T. New therapies for GI cancers fall short. JAMA 2009;302:373-374.
4. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322: 352-358.
5. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993;341:457-460.
6. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
7. Chau I, Cunningham D. Treatment in advanced color-ectal cancer: what, when and how? Br J Cancer 2009;100:1704-10719.
8. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-1174.
9. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009;27:3385-3390.
10. Nagano M, Chastre E, Choquet A, et al. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol 1995;268:431-442.
11. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225-268.
12. Clevenger CV, Zheng J, Jablonski EM, et al. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia 2008;13:147-156.
13. Reynolds C, Montone KT, Powell CM, et al. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997;138:5555-5560.
14. Vonderhaar BK. Prolactin involvement in breast cancer. Endocr Relat Cancer 1999;6:389-404.
15. Tallet E, Rouet V, Jomain JB, et al. Rational design of competitive prolactin/growth hormone receptor antagonists. J Mammary Gland Biol Neoplasia 2008; 13:105-117.
16. Walker AM. Therapeutic potential of S179D prolactin-from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator. Expert Opin Investig Drugs 2006;15:1257-1267.
17. Goffin V, Bernichtein S, Touraine P, et al. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005;26:400-422.
18. Bhatavdekar J, Patel D, Ghosh N, et al. Interrelationship of prolactin and its receptor in carcinoma of colon and rectum: a preliminary report. J Surg Oncol 1994;55:246-249.
19. Bhatavdekar JM, Patel DD, Chikhlikar PR, et al. Ectopic production of prolactin by colorectal adenocarcinoma. Dis Colon Rectum 2001;44:119-127.
20. Otte JM, Otte C, Beckedorf S, et al. Expression of functional prolactin and its receptor in colorectal cancer. Int J Coloretal Dis 2003;18:86-94.
21. Sobin LH, Wittekind C, (eds) TNM Classification of Malignant Tumors, 6th edn. Wiley-Liss: New York, 2002.
22. Hamilton SR, Vogelstein B, Kudo S, et al. Carcinoma of the colon and rectum In: Hamilton SR, Aaltonen LA (eds). World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Digestive System. IARC Press: Lyon, 2000, pp 105-119.
23. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
24. Kersten HM, Robben JC, Poddinghe PJ, et al. AgarCyto: a novel cell processing method for multiple molecular diagnostic analyses of uterine cervix. J Histochem Cytochem 2000;48:709-718.
25. Ben-Jonathan N, Mershon JL, Allen DL, et al. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17: 639-669.
26. De Vries JE, Dinjens WN, De Bruyne GK, et al. In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br J Cancer 1995;71:271-277.
27. Baert D, Matthys C, Gillardin JP, et al. Prolactin and colorectal cancer: is there a connection? Acta Gastro-enterol Belg 1998;61:407-409.
28. Carlson HE, Zarrabi MH, Lyubsky SL. Lack of association between hyperprolactinemia and colon carcinoma. Cancer Invest 2000;18:130-134.
29. Wood AJ, Thomas CM, Baumforth KRN, et al. Absence of prolactin gene expression in colorectal cancer. J Clin Pathol 1999;52:135-139.
30. Bhatavdekar JM, Patel DD, Chikhlikar PR, et al. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001;44:523-533.
31. Ilan Y, Sibirsky O, Livni N, et al. Plasma and tumor prolactin in colorectal cancer patients. Dig Dis Sci 1995;40:2010-2015.
32. Indinnimeo M, Cicchini C, Memeo L, et al. Plasma and tissue prolactin detection in colon carcinoma. Oncol Rep 2001;8:1351-1353.
33. Carver KC, Arendt LM, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol Cell Endocrinol 2009;307:1-7.
34. Bernichtein S, Kayser C, Dillner K, et al. Development of pure prolactin receptor antagonists. J Biol Chem 2003;278:35988-35999.
35. Beck MT, Chen NY, Franek KJ, et al. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res 2003;63:3598-3604.
36. Langenheim JF, Chen WY. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. Breast Cancer Res Treat 2005;90: 281-293.
37. Frontini L, Lissoni P, Vaghi M, et al. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pre-treated metastatic breast cancer. Anticancer Res 2004;24:4223-4226.